TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07760155: A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus

Sponsor: Shanghai Escugen Biotechnology Co., Ltd · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$414,000

Rescue Site Savings

+$276,000

Unlock Full NCT07760155 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07760155 Rescue Dossier →